Yingke Biopharmaceutical has raised 300 million yuan ($42.4 million) in a Series B round led by Hong Kong-listed China Life Insurance’s private equity arm as it looks to expand its operations across the country.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $52.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at firstname.lastname@example.org